Detalles de la búsqueda
1.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Lancet Oncol
; 25(6): 707-719, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38710187
2.
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Gynecol Oncol
; 181: 162-169, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38211393
3.
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
BMC Cancer
; 23(1): 182, 2023 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36814246
4.
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.
Br J Cancer
; 126(7): 1010-1017, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34903842
5.
Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.
Acta Oncol
; 61(12): 1499-1506, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36529989
6.
Precision patients: Selection practices and moral pathfinding in experimental oncology.
Sociol Health Illn
; 44(2): 345-359, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34993996
7.
Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Cytotherapy
; 22(4): 204-213, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32201034
8.
Gene therapy for patients with advanced solid tumors: a phase I study using gene electrotransfer to muscle with the integrin inhibitor plasmid AMEP.
Acta Oncol
; 56(7): 909-916, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28438067
9.
Cytokine release syndrome caused by antineoplastic treatment with CAR-T and T-cell engaging therapies.
Ugeskr Laeger
; 186(9)2024 02 26.
Artículo
en Da
| MEDLINE | ID: mdl-38445322
10.
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Nat Med
; 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38710951
11.
New pathogenic germline variants identified in mesothelioma.
Lung Cancer
; 179: 107172, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36944283
12.
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.
Sci Transl Med
; 15(695): eabp9229, 2023 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163618
13.
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
Nat Commun
; 14(1): 630, 2023 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36746967
14.
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor.
Adv Healthc Mater
; 11(1): e2100684, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34734500
15.
Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types.
Front Oncol
; 11: 558248, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33842304
16.
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
NPJ Breast Cancer
; 7(1): 44, 2021 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33863913
17.
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
Cancer Discov
; 10(2): 198-213, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31806627
18.
[Trends in oncological phase I trials].
Ugeskr Laeger
; 181(20A)2019 Oct 14.
Artículo
en Da
| MEDLINE | ID: mdl-31610836
19.
Application of cell-free DNA for genomic tumor profiling: a feasibility study.
Oncotarget
; 10(14): 1388-1398, 2019 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30858924
20.
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Clin Cancer Res
; 25(4): 1239-1247, 2019 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30274980